November 2025 Changes to the QTdrugs List and List of Drugs to Avoid in CLQTS

November 7, 2025

The AZCERT Scientific Review Committee has found substantial evidence that the new drug Dordaviprone (anti-cancer medication) is associated with the development of QT prolongation but lacks convincing evidence of causing torsades de pointes (TdP). Therefore, this drug has been added to the Possible Risk of TdP category (PR) and to the List of Drugs to Avoid in patients with Congenital Long QT Syndrome (DTA List). The committee also found that the drug Cinacalcet (hyperparathyroidism treatment) is associated with prolongation of the QT interval as well as cases of TdP under certain conditions (hypocalcemia). Therefore, this drug has been added to the Conditional Risk of TdP category (CR) and to the List of Drugs to Avoid in patients with Congenital Long QT Syndrome (DTA List).

As demonstrated by these revisions, the QTdrugs list is dynamic and changes regularly.  To perform a quick search of the QTdrugs and DTA Lists, we recommend using the CredibleMeds website and/or the smartphone app (Apple or Android).